Roche FDA-accepted sBLA for adjuvant Tecentriq plus chemo in stage III dMMR-MSI-H colon cancer backed by ATOMIC data shows 50% reduction in recurrence, signaling growing biologics API manufacturing demand.

GlaxoSmithKline 10.6 billion acquisition of Nuvalent adds three precision oncology assets targeting ROS1, ALK, and HER2-mutant NSCLC, creating immediate demand for high-complexity small-molecule API manufacturing capacity across the global supply chain.

Samsung Biologics 353 million acquisition of GSK biologics manufacturing facility in Rockville Maryland marks the Korean CDMO giant first U.S. production presence and signals a strategic inflection in the global CDMO landscape.

Pfizer and Innovent Biologics have struck one of the largest oncology licensing deals in pharmaceutical history, committing up to $10.5 billion for a 12-program cancer portfolio spanning antibody-drug conjugates and multispecific antibodies.